M
Metapines
Novel pharmaceutical composition for cancer treatment, where different compounds are simultaneously uptaken into cancer cells
About Metapines
Metafines is a pioneering company in the field of cancer treatment, specializing in the research and development of advanced anti-cancer drugs. The company's core technology focuses on metabolic anti-cancer drugs that target the metabolic processes of cancer cells through multiple mechanisms. These drugs work by disrupting the metabolic activities of cancer cells in complex ways, utilizing different compounds that act simultaneously on each cancer cell. Metafines serves the healthcare and pharmaceutical markets, primarily targeting medical institutions and oncology specialists. The business model revolves around the development and commercialization of these innovative drugs, generating revenue through sales and licensing agreements. The company operates in a highly specialized niche within the pharmaceutical industry, aiming to provide effective treatment options for various types of cancer.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Seongnam-si, South Korea
- Open positions
- None listed
- Dealroom signal
- 21.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Latest news
Press, funding announcements and product moves mentioning Metapines.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Apr 2022 | $17M | $67M | Industrial Bank of Korea · Meritz Capital · IP Ventures-Middle East Finance · DSC Investment | ↗ |
| SERIES AEquity / VC | Dec 2018 | $7.5M | $30M | DSC Investment | ↗ |
Growth signals
Latest recorded traffic for Metapines is 1.7K monthly website visits, up 900% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
DSC Investment
Industrial Bank of Korea- MCMeritz Capital
- IFIP Ventures-Middle East Finance
Prodigy Investment
Meritz Securities
S&S Investment- BKBM Korea
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Metapines on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Metapines’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.